Alnylam's Phase III Results For Vutrisiran Are 'Foundation' For Amyloidosis Expansion

FDA Filing Anticipated In Early 2021

 
• By Alaric DeArment
  
nerve cells, concept for neurodegenerative and neurological disease
Alnylam announces positive Phase III results for vutrisiran in hATTR amyloidosis with polyneuropathy. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Scrip